Tokyo Tape
Sign in
← Alfresa Holdings

Quarterly report · Q3

2784.TEDINET S100SVSS
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥2.18T2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥2.70T2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥2.05T2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥29.9bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥20.0bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥31.2bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥32.8bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥22.0bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥30.9bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥22.7bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥20.9bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥25.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥14.8bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥20.9bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥14.9bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥1.50Tat 2023-12-31Cons.Assets
Total assets¥1.34Tat 2023-03-31Cons.Assets
Total assets¥1.44Tat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥1.04Tat 2023-12-31Cons.Liabilities
Total liabilities¥851.5bnat 2023-03-31Cons.Liabilities
Net assets / equity¥464.3bnat 2023-12-31Cons.Net assets
Net assets / equity¥488.3bnat 2023-03-31Cons.Net assets
Net assets / equity¥481.9bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥200.8bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥160.1bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥107.922023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥48.222023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥127.422022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥73.242022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥38.642022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio30.9%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.4%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio33.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 45
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥26.2bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥26.2bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31¥290m
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥1.94T
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥1.92T
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥14.0bn
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥25.9bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥40.0bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥28.2bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥11.7bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥1.1bn
jpcrp040300-q3r_E02962-000Medical Related Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥27.5bn
jpcrp040300-q3r_E02962-000Medical Related Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥27.5bn
jpcrp040300-q3r_E02962-000Medical Related Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥484m
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥200.4bn
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥200.0bn
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥395m
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥2.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-12-31¥2.21T
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-12-31¥2.18T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-12-31¥26.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-12-31¥29.7bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥24.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥24.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31¥372m
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥1.82T
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.81T
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥13.1bn
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥16.9bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥36.4bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥25.8bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥10.6bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥992m
jpcrp040300-q3r_E02962-000Medical Related Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥27.1bn
jpcrp040300-q3r_E02962-000Medical Related Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥27.1bn
jpcrp040300-q3r_E02962-000Medical Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥0
jpcrp040300-q3r_E02962-000Medical Related Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥43m
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥186.8bn
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥186.3bn
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥429m
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥2.07T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥2.05T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥24.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥19.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 381
ItemContextValueUnit
Valuation and translation adjustmentsCurrentQuarterInstant48456000000JPY
Non controlling interestsPrior1YearInstant244000000JPY
Non controlling interestsCurrentQuarterInstant302000000JPY
Net assetsPrior1YearInstant488335000000JPY
Net assetsCurrentQuarterInstant464343000000JPY
Liabilities and net assetsPrior1YearInstant1339852000000JPY
Liabilities and net assetsCurrentQuarterInstant1500114000000JPY
Net salesPrior1YTDDuration2047935000000JPY
Net salesCurrentYTDDuration2179803000000JPY
Cost of salesPrior1YTDDuration1906213000000JPY
Cost of salesCurrentYTDDuration2025508000000JPY
Gross profitPrior1YTDDuration141722000000JPY
Gross profitCurrentYTDDuration154294000000JPY
Selling general and administrative expensesPrior1YTDDuration121721000000JPY
Selling general and administrative expensesCurrentYTDDuration124350000000JPY
Operating incomePrior1YTDDuration20000000000JPY
Operating incomeCurrentYTDDuration29944000000JPY
Interest income noiPrior1YTDDuration38000000JPY
Interest income noiCurrentYTDDuration40000000JPY
Dividends income noiPrior1YTDDuration1179000000JPY
Dividends income noiCurrentYTDDuration1163000000JPY
Real estate rent noiPrior1YTDDuration443000000JPY
Real estate rent noiCurrentYTDDuration404000000JPY
Other noiPrior1YTDDuration627000000JPY
Other noiCurrentYTDDuration713000000JPY
Non operating incomePrior1YTDDuration2288000000JPY
Non operating incomeCurrentYTDDuration2322000000JPY
Interest expenses noePrior1YTDDuration49000000JPY
Interest expenses noeCurrentYTDDuration67000000JPY
Commission fee noePrior1YTDDuration－JPY
Commission fee noeCurrentYTDDuration624000000JPY
Rent expenses on real estates noePrior1YTDDuration136000000JPY
Rent expenses on real estates noeCurrentYTDDuration138000000JPY
Other noePrior1YTDDuration110000000JPY
Other noeCurrentYTDDuration221000000JPY
Non operating expensesPrior1YTDDuration296000000JPY
Non operating expensesCurrentYTDDuration1051000000JPY
Ordinary incomePrior1YTDDuration21992000000JPY
Ordinary incomeCurrentYTDDuration31215000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration106000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration199000000JPY
Gain on sales of investment securities eiPrior1YTDDuration2686000000JPY
Gain on sales of investment securities eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration2792000000JPY
Extraordinary incomeCurrentYTDDuration199000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration15000000JPY
Loss on sales of noncurrent assets elCurrentYTDDuration100000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration77000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration135000000JPY
Impairment loss elPrior1YTDDuration1000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass